Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113483163 | 11348316 | 3 | F | 201206 | 20160726 | 20150806 | 20160804 | PER | US-BAYER-2015-394959 | BAYER | 31.00 | YR | A | F | Y | 0.00000 | 20160804 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113483163 | 11348316 | 1 | PS | MIRENA | LEVONORGESTREL | 1 | Intra-uterine | 20 MCG/24HR, CONT | Y | TU00E3A | 21225 | 20 | UG | INTRAUTERINE DELIVERY SYSTEM | |||||
| 113483163 | 11348316 | 2 | C | LORTAB | ACETAMINOPHENHYDROCODONE BITARTRATE | 1 | Oral | 5/325MG, 1-2,EVERY 4 HOURS AS NEEDED | 0 | ||||||||||
| 113483163 | 11348316 | 3 | C | HYDROCODONE W/ACETAMINOPHEN | ACETAMINOPHENHYDROCODONE BITARTRATE | 1 | Oral | 1 TABLET, EVERY 6 HOURS, AS NEEDED, TABLET 5-500 MG | 0 | ||||||||||
| 113483163 | 11348316 | 4 | C | TYLENOL WITH CODEINE | ACETAMINOPHENCODEINE PHOSPHATE | 1 | 0 | ||||||||||||
| 113483163 | 11348316 | 5 | C | IBUPROFEN. | IBUPROFEN | 1 | 0 | ||||||||||||
| 113483163 | 11348316 | 6 | C | NORCO | ACETAMINOPHENHYDROCODONE BITARTRATE | 1 | Oral | ONE TABLET, AS NEEDED5-325 MG | 0 | ||||||||||
| 113483163 | 11348316 | 7 | C | MACROBID | NITROFURANTOINNITROFURANTOIN MONOHYDRATE | 1 | ONE TABLET, TWICE A DAY | 0 | |||||||||||
| 113483163 | 11348316 | 8 | C | NITROFURANTOIN MACROCRYSTALS | NITROFURANTOIN | 1 | Oral | 100 MG CAPSULE ONE, TWO TIMES DAILY | 0 | ||||||||||
| 113483163 | 11348316 | 9 | C | EPINEPHRINE. | EPINEPHRINE | 1 | 0.3 MG/0.3ML, AS NEEDED WITH WASP STINGS | 0 | |||||||||||
| 113483163 | 11348316 | 10 | C | PRENATAL VITAMINS | VITAMINS | 1 | UNK UNK, QD | 0 | QD | ||||||||||
| 113483163 | 11348316 | 11 | C | SERTRALINE HYDROCHLORIDE. | SERTRALINE HYDROCHLORIDE | 1 | Oral | 50 MG, QD | 0 | 50 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 113483163 | 11348316 | 1 | Contraception |
| 113483163 | 11348316 | 2 | Pain |
| 113483163 | 11348316 | 3 | Pain |
| 113483163 | 11348316 | 7 | Urinary tract infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 113483163 | 11348316 | HO |
| 113483163 | 11348316 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 113483163 | 11348316 | Device dislocation | |
| 113483163 | 11348316 | Device failure | |
| 113483163 | 11348316 | Device issue | |
| 113483163 | 11348316 | Injury | |
| 113483163 | 11348316 | Maternal exposure before pregnancy | |
| 113483163 | 11348316 | Menorrhagia | |
| 113483163 | 11348316 | Uterine perforation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 113483163 | 11348316 | 1 | 20120613 | 20131003 | 0 |